Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System Bharati BhardwajaShilpa KlockeKari L. Olson Leading Article 24 November 2021 Pages: 1 - 11
Targeting Nuclear Export Proteins in Multiple Myeloma Therapy Shambavi RichardSundar Jagannath Review Article 03 February 2022 Pages: 13 - 25
Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review Rosanne W. MeijboomHelga GardarsdottirThijs J. Giezen Systematic Review Open access 06 December 2021 Pages: 27 - 39
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin Andreas VolkCaroline Covini-SourisTorben Schmidt Original Research Article Open access 29 November 2021 Pages: 41 - 53
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study Rubi K. LiEriko TokunagaOleg Lipatov Original Research Article Open access 08 February 2022 Pages: 55 - 69
Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians Jingyan YangKelly BlinzlerAhmed Shelbaya Original Research Article Open access 25 November 2021 Pages: 71 - 83
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn’s Disease Pavine L. C. LefevreParambir S. DulaiNiels Vande Casteele Original Research Article 24 December 2021 Pages: 85 - 93
